Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients

Basnyat, Pabitra; Hagman, Sanna; Kolasa, Marcin; Koivisto, Keijo; Verkkoniemi-Ahola, Auli; Airas, Laura; Elovaara, Irina

doi:10.1016/j.msard.2015.06.008

Cited by 13 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spadaro et al confirmed that natalizumab specifically decreased CD62LCD4 + cells. Basnyat et al reported a significant correlation between JCV serostatus and level of soluble L‐selectin, while Schwab et al have confirmed that both anti‐JCV antibodies and CD62L levels have merit for risk stratification and could be developed into a risk algorithm that could reduce PML incidence. There is also a report that CD62L might be a biomarker for HIV+ PML .…”

Section: Tests Involving Minimally Invasive Assaysmentioning

confidence: 99%

Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy

White

Sariyer

Gordon

et al. 2015

Reviews in Medical Virology

View full text Add to dashboard Cite

SUMMARY Progressive multifocal leukoencephalopathy (PML) is a devastating and often fatal demyelinating disease of the central nervous system (CNS) for which effective therapies are lacking. It is caused by the replication of polyomavirus JC (JCV) in the oligodendrocytes and astrocytes leading to their cytolytic death and loss of myelin from the subcortical white matter. While the virus is very common in human populations worldwide, the incidence of the disease is very low and confined almost exclusively to individuals with some form of immunological dysfunction. However, the number of people who constitute the at-risk population is growing larger and includes individuals with HIV-1/AIDS and patients receiving immunomodulatory therapies such as multiple sclerosis patients treated with natalizumab. Further adding to the public health significance of this disease are the difficulties encountered in the diagnosis of PML and the lack of useful biomarkers for PML progression. In this review, we examine the diagnostic assays that are available for different aspects of the JCV life cycle, their usefulness and drawbacks, and the prospects for improvements.

show abstract

Section: Tests Involving Minimally Invasive Assaysmentioning

confidence: 99%

Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy

White

Sariyer

Gordon

et al. 2015

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…The report of Basnyat et al showed a significant, but weak, correlation between levels of soluble L-selectin and JCV antibody index in patients treated with natalizumab. This supports a possible role of Lselectin in the pathogenesis of natalizumab-associated PML (progressive multifocal leukoencephalopathy) (Basnyat et al, 2015). Reduced levels of L-selectin-expressing CD4-positive cells in the peripheral blood have been associated with an increased risk of developing natalizumab-associated PML (Schwab et al, 2013).…”

mentioning

confidence: 56%

Editors’ Welcome

Banwell¹,

Giovannoni²,

Hawkes³

et al. 2015

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…As a further confirmation, it was recently shown that in addition to the cellular form, soluble CD62L also correlates with JCV index in natalizumab-treated MS patients. 20 In a similar line of thought it makes sense that in the first 17 months of treatment, when the PML incidence is much lower, none of 69 patients was set as CD62L low. As previous hypotheses concerning JCV titers suggested that higher titers are the result of a higher replication rate of the virus, [21][22][23] it is conceivable that a higher replication rate is due to the fact that the lessviable immune cells of this patient are less capable of suppressing viral activity.…”

Section: Discussionmentioning

confidence: 98%